All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Neurology Drugs in Phase III Clinical Development in KOREA, REPUBLIC OF

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

GNT Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

GNT Pharma's Anti-dementia Drug 'crisdesalazine' Demonstrates Efficacy in Phase III Clinical Study with Companion Dogs with Dementia

Contact the Supplier

Lead Product(s): Crisdesalazine

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

Crisdesalazine demonstrated significant improvement in cognition function in the primary outcome measure